Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency

NCT ID: NCT00771446

Last Updated: 2013-04-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2009-04-30

Brief Summary

Evaluate on how well the ELAD system works in treating people with liver failure.

Detailed Description

This is a multicenter, open-label, randomized, concurrent control study of subjects with acute on chronic hepatitis. Subjects meeting the eligibility requirements of the study will be randomly assigned in a 2:1 ratio to receive either standard medical therapy for acute liver failure plus the ELAD system, or standard medical therapy alone, with the latter defined as conventional therapy for acute on chronic hepatitis determined to be clinically appropriate by the treating physician.

Immediately prior to treatment initiation, subject eligibility will be confirmed. Treatment with ELAD will continue for a minimum of 3 days and up to a maximum of 10 days or until clinical status improves relative to study entry. Subjects will be followed until 30 days has elapsed since study enrollment (control) or 30 days has elapsed since cessation of ELAD therapy (ELAD group), whichever comes first.

Conditions

Acute Hepatitis; Chronic Hepatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ELAD (plus Standard of Care)

Treatment with ELAD in addition to standard of care therapy Standard of care therapy defines uniform treatment for ascites, esophageal varices, dietary recommendations, etc.

Group Type: EXPERIMENTAL

ELAD plus standard of care treatment

Intervention Type: BIOLOGICAL

ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Standard of care treatment

Intervention Type: OTHER

Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Standard of Care (Control)

Standard of care treatment Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Group Type: OTHER

Standard of care treatment

Intervention Type: OTHER

Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Interventions

ELAD plus standard of care treatment

ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Intervention Type: BIOLOGICAL

Standard of care treatment

Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Weight >40 kilograms

2. Age >18 and <70 years

3. Acute decompensation of cirrhosis over the preceding 48-72 hour period

4. Up to 4 weeks from symptom onset to presentation

5. Presence of a precipitating event

6. Either a MELD score of ≥32, or ≥24 with one or more of the following

• Severe encephalopathy of grade 3 or 4 on the Westhaven scale
• Renal dysfunction typical of type-1 hepato-renal syndrome, i.e. acute renal failure without evidence of elevated serum creatinine (>2.5mg/dL) during the 1 to 6 months prior to study entry. Serum creatinine at study entry >2.5mg/dL does not exclude the subject from enrolment

7. SOFA score ≥9 at the initial Screening Visit

Exclusion Criteria

1. Platelets <50,000 or reducing to <80,000 over a 72 hour period

2. Renal failure: Serum creatinine ≥2.5 mg/dL as measured during the 1 - 6 month period prior to study entry. If a subject has a contraindication to renal replacement therapy (hemodialysis or hemofiltration), then the subject should be excluded from entry into the study

3. Active sepsis. Sepsis will be defined as positive microbiological culture, ascitic white cell count >450 cells/mm³ (or ascitic neutrophil count >250 cells/mm³), or clinical signs and chest x-ray appearances for at least 48 hours without clinical improvement prior to randomization, or other evidence of infection not under control

4. Evidence of major hemorrhage indicated by requiring ≥ 4 unit blood transfusion within a 24 hour period, or hemodynamic instability (sustained pulse >120 beats/min and systolic blood pressure <100 mmHg over one hour). Subjects with a recent history of gastrointestinal hemorrhage who have been successfully treated and remain hemodynamically stable for a period of 48 hours will then be eligible for the study

5. Evidence (by physical exam, history, or laboratory evaluation) of significant concomitant disease including chronic congestive heart failure, vascular disease, emphysema, AIDS, fatty-liver disease of non-alcoholic origin, hepatitis due to herpes virus, Wilson's disease, or Budd-Chiari syndrome;

6. Known history of hepatocellular carcinoma beyond the Milan criteria and/or portal vein thrombosis

7. Evidence of Small Bowel Perforation within 48 hours of treatment;

8. Evidence of brain death as determined by blood flow studies positive for herniation and/or absence of pupillary reflex

9. Mean Arterial Pressures (MAP) < 50 mm Hg for one hour or longer;

10. Requirement for escalating doses of vasopressor support of an alpha-adrenergic agent for one hour or longer and evidence of hemodynamic instability;

11. Clinical or radiographic evidence of a new stroke or intracerebral bleeding

12. Seizures uncontrolled by medication

13. Acute myocardial infarction based on clinical and/or electrocardiographic evidence

14. Lung disease defined by a PaO2 <60 mm Hg or a history of severe COPD or interstitial lung disease

15. Pregnancy as determined by βHCG results, or lactation

16. Participation in another investigational drug, biologic, or device study within one month of enrollment

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 69 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vital Therapies, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Todd Frederick, MD

Role: PRINCIPAL_INVESTIGATOR

California Pacific Medical Center

Donald Hillebrand, MD

Role: PRINCIPAL_INVESTIGATOR

Scripps Green Hospital

Helen Te, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Robert Brown, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Lena Napolitano, MD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan Hospital

Winfred Williams, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Scripps Clinic

La Jolla, California, United States

California Pacific Medical Center

San Francisco, California, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

University of Michigan Hospital

Ann Arbor, Michigan, United States

Columbia University Medical Center

New York, New York, United States

Countries

United States

Other Identifiers

VTI-201

Identifier Type: -

Identifier Source: org_study_id